A susceptibility locus for classical Hodgkin lymphoma at 8q24 near MYC / PVT1 predicts patient outcome in two independent cohorts

Hervé Ghesquières (1, 2, 3) , Beth R. Larrabee (3) , Olivier Casasnovas (4) , Matthew Maurer (3) , James D. Mckay (5) , Stephen Ansell (6) , Dorothy Montgomery (7) , Yann W. Asmann (3) , Katrina Farrell (7) , Aurélie Verney (2) , Susan Slager (3) , Cristine Allmer (3) , Aurore Perrot (8) , Richard Delarue (9) , Thomas M Habermann (6) , Jehan Dupuis (10, 11) , Brian Link (12) , Danielle Canioni (13) , Ahmet Dogan (14) , Wendy Cozen (15) , Ruth F. Jarrett (7) , James R. Cerhan (3) , Gilles Salles (2, 1)

1 Service d’Hématologie [Centre Hospitalier Lyon Sud - HCL]
2 UNICANCER/CRCL - Centre de Recherche en Cancérologie de Lyon
3 HSR - Department of Health Sciences Research [Mayo Clinic]
4 Service d'Hématologie Clinique (CHU de Dijon)
5 IACR - International Agency for Cancer Research
6 Mayo Clinic [Rochester]
7 MRC - University of Glasgow Centre for Virus Research
8 Service d'Hématologie [CHRU Nancy]
9 Service d'immuno-hématologie pédiatrique [CHU Necker]
10 Service d'hématologie clinique
11 Hôpital Henri Mondor
12 Carver College of Medicine, University of Iowa
13 Service de pathologie [CHU Necker]
14 Memorial Sloane Kettering Cancer Center [New York]
15 Norris Comprehensive Cancer Center

Mots clés: MYC; PVT1; Hodgkin lymphoma; polymorphism; prognostic; susceptibility

Domaines: Sciences du Vivant [q-bio]; Cancer

Hervé Ghesquières, Beth R. Larrabee, Olivier Casasnovas, Matthew Maurer, James D. Mckay, et al.. A susceptibility locus for classical Hodgkin lymphoma at 8q24 near MYC / PVT1 predicts patient outcome in two independent cohorts. British Journal of Haematology, 2018, 180 (2), pp.286 - 290. ⟨10.1111/bjh.14306⟩. ⟨hal-01728832⟩